IDEA Collider | Pharma Book Club | Dr Jeremy Levin
IDEA Collider
English - June 23, 2020 17:18 - 43 minutes - 40.2 MB - ★★★★★ - 2 ratingsLife Sciences Science Business pharmaceutical innovation author interviews book club book reviews pharmaceuticals innovation pharma Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA) Before Teva, Dr. Levin was member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity he was the architect of and implemented the String of Pearls Strategy, which transformed Bristol. Dr. Levin joined BMY from Novartis (SWX: NOVN) where he was global head of strategic alliances. He has served on the board of directors of various public and private biopharmaceutical companies and is currently on the board of directors of Lundbeck (OMX: LUN). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement. He has practiced medicine at university hospitals in England, South Africa, and Switzerland. Dr. Levin earned his bachelor’s degree in zoology and a master’s degree and doctorate in chromatin structure, at the University of Oxford, and thereafter his medical and surgical degrees from the University of Cambridge where he won the Kermode Prize for his work on Captopril.
Authors of individual chapters
HISTORICAL PERSPECTIVES
Vicki L. Sato, Stelios Papadopoulos, Sam Waksal, Bill Sibold, Frederick Frank Q&A with a Biotech Pioneer, Brook Byers, Sol Barer
PERSONAL PERSPECTIVES
Michelle McMurry-Heath, Andy Plump, Kiran Mazumdar-Shaw, Karen Bernstein, Ron Cohen, Samantha Du, Cedric François
THE VIEW FROM INSIDE COMPANIES
George Scangos, John Young, Stéphane Bancel, Jean-Pierre Sommadossi, John V. Oyler, Paul Hastings, Christi Shaw, John Maraganore, Rachel King, Richard Pops, Deborah Dunsire
BROAD LESSONS
Kenneth I. Moch, Quita Highsmith, Luke Rosen, Sylvia Wulf, Philip Miller, Alex Zhavoronkov and Evelyne Bischof
LEADERSHIP
Jeffrey M. Solomon, Julie Louise Gerberding, Jeff Berkowitz, James Greenwood
INVESTOR PERSPECTIVES
Nina Kjellson, Bruce Booth, Alexander Karnal, Mark Lampert, Geoff Porges
LOOKING TO THE FUTURE
Peter Kolchinsky, Yaron Werber, Jeff Kindler, Otello Stampacchia